Table 1 Demographics and cognitive profiles (Aβ positivity determined by the SUVR cutoff).

From: Elevated cerebral blood flow proxy with increased beta-amyloid burden in Alzheimer’s disease preclinical phase evaluated by dual-phase 18F-florbetaben positron emission tomography

 

Total (n = 71)

Aβ−NC (n = 40)

Aβ+NC (n = 31)

p-value

Demographics

 Age, years

73.24 ± 5.57

72.78 ± 5.43

73.84 ± 5.79

0.433

 Female, %

78.87%

86.64%

75.00%

> 0.99

 Education, years

9.82 ± 4.17

10.78 ± 4.16

8.58 ± 3.91

0.025*

 APOE4 carrier†

18.18%

13.16%

25.00%

0.362

Cognitive profiles

 MMSE score

28.38 ± 1.44

28.45 ± 1.4

28.29 ± 1.51

0.649

 Global CDR

0.31 ± 0.24

0.35 ± 0.23

0.26 ± 0.25

0.121

 Attention

  Digit span Forward

0.26 ± 0.96

0.32 ± 0.94

0.18 ± 0.99

0.549

  Digit span Backward

0.3 ± 0.98

0.39 ± 1.16

0.19 ± 0.68

0.350

 Language

  Naming K-BNT

0.2 ± 0.91

0.21 ± 0.74

0.18 ± 1.1

0.881

 Visuospatial

  RCFT copy

0.06 ± 0.9

0.17 ± 0.7

− 0.08 ± 1.11

0.273

 Memory

  SVLT Delayed recall

0.59 ± 0.98

0.57 ± 1

0.61 ± 0.96

0.873

  RCFT delayed recall

0.37 ± 1.01

0.32 ± 0.97

0.45 ± 1.07

0.596

 Frontal Executive function

  COWAT phonemic

0.78 ± 1.28

0.8 ± 1.4

0.74 ± 1.12

0.849

  StroopTest Color reading correct

0.51 ± 0.9

0.61 ± 0.86

0.39 ± 0.95

0.321

  1. Values are expressed as mean with standard deviation. p-values were calculated using the Two sample t-test. *p-values indicate significance at the 0.05 level. †APOE4 genotyping was missed in two participants in the Aβ−NC group and four participants in the Aβ+NC group. Aβ−NC, Aβ-negative cognitively normal; Aβ+NC, Aβ-positive cognitively normal; APOE, apolipoprotein E; MMSE, Mini-Mental State Examination; CDR, Clinical Dementia Rating; K-BNT, Korean version of the Boston Naming Test; RCFT, Rey–Osterrieth Complex Figure Test; SVLT, Seoul Verbal Learning Test; COWAT, Controlled Oral Word Association Test.
Back to article page